Marker Therapeutics (FRA:GX1) 5-Year EBITDA Growth Rate : 37.80% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics 5-Year EBITDA Growth Rate?

Marker Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was €0.28.

During the past 3 years, the average EBITDA Per Share Growth Rate was 52.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 37.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 40.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Marker Therapeutics was 70.20% per year. The lowest was 5.90% per year. And the median was 24.30% per year.

Competitive Comparison of Marker Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Marker Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Marker Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Marker Therapeutics (FRA:GX1) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Marker Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

2450 Holcombe Boulevard, Suite e BCM-A, MS: BCM251, Houston, TX, USA, 77021

Website

https://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Headlines

No Headlines